Poseida Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Loss on disposal of property and equipment
Stock-based compensation
Write off of deferred CIRM grant liability
Change in fair value of warrant liability
Accretion of discount on issued term debt
Accretion of investment discount, net
Amortization of premium and accretion of discounts on investments, net
Accretion on investment securities, net

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other long-term assets
Accounts payable
Accrued liabilities
Accrued expenses and other liabilities
Operating lease liabilities
Deferred revenue
Net cash used in operating activities
Investing Activities:
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of short-term investments
Proceeds from maturities of short-term investments
Net cash provided by (used in) investing activities
Financing Activities:
Net proceeds from stock option exercises
Proceeds from issuance of common stock under employee stock compensation plans
Issuance of Series D financing, net of issuance costs
Series D Convertible Preferred Stock
Total issuance of Series D financing, net of issuance costs
Proceeds from initial public offering, net of issuance costs
Payment of taxes related to net share settlement of equity awards
Proceeds from issuance of common stock through ATM offering, net of issuance costs
Proceeds from private placement of common stock
Proceeds from public offering of common stock, net of issuance costs
Proceeds from term debt
Payment of debt issuance costs
Net proceeds from CIRM grant awards
Net cash provided by financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Non-cash operating, investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued liabilities
Tenant improvement receivable from landlord
Right-of-use assets and lease liabilities
Right-of-use assets obtained in exchange for operating lease liabilities
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering

Supplemental disclosure of cash flow information:
Interest paid

Comments